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Cytochrome P450 2E1 (CYP2E1) is a key enzyme in the met-
abolic activation of many low molecular weight toxicants and 
also an important contributor to oxidative stress. A noninvasive 
method to monitor CYP2E1 activity in vivo would be of great value 
for studying the role of CYP2E1 in chemical-induced toxicities 
and stress-related diseases. In this study, a mass spectrometry–
based metabolomic approach was used to identify a metabolite 
biomarker of CYP2E1 through comparing the urine metabolomes 
of wild-type (WT), Cyp2e1-null, and CYP2E1-humanized mice. 
Metabolomic analysis with multivariate models of urine metab-
olites revealed a clear separation of Cyp2e1-null mice from WT 
and CYP2E1-humanized mice in the multivariate models of urine 
metabolomes. Subsequently, 2-piperidone was identified as a uri-
nary metabolite that inversely correlated to the CYP2E1 activity 
in the three mouse lines. Backcrossing of WT and Cyp2e1-null 
mice, together with targeted analysis of 2-piperidone in mouse 
serum, confirmed the genotype dependency of 2-piperidone. The 
accumulation of 2-piperidone in the Cyp2e1-null mice was mainly 
caused by the changes in the biosynthesis and degradation of 
2-piperidone because compared with the WT mice, the conversion 
of cadaverine to 2-piperidone was higher, whereas the metabo-
lism of 2-piperidone to 6-hydroxy-2-piperidone was lower in the 
Cyp2e1-null mice. Overall, untargeted metabolomic analysis iden-
tified a correlation between 2-piperidone concentrations in urine 
and the expression and activity of CYP2E1, thus providing a non-
invasive metabolite biomarker that can be potentially used in to 
monitor CYP2E1 activity.
Key Words: CYP2E1; biomarker; metabolomics; 2-piperidone; 
cadaverine.
Cytochromes P450 (P450) are the most important enzymes 
in xenobiotic metabolism (Guengerich and Cheng, 2011). 
CYP2E1 is involved in the oxidative metabolism of numerous 
therapeutic agents and environmentally important chemicals 
such as alcohol, aliphatic and aromatic hydrocarbons, and 
solvents and industrial monomers. Many CYP2E1-catalyzed 
reactions not only generate reactive metabolites but also pro-
duce reactive oxygen species (ROS), such as superoxide and 
hydrogen peroxide (Trafalis et al., 2010). The involvement of 
CYP2E1 in metabolic bioactivation of oxidative stress indicates 
that this P450 plays an important role in many toxic events, par-
ticularly in the liver where it is constitutively expressed (Caro 
and Cederbaum, 2004). It was shown that CYP2E1-catalyzed 
biotransformation might be responsible for some chemical-
induced carcinogenesis (Leon-Buitimea et  al., 2012; Trafalis 
et  al., 2010) and tissue injury (Chen et  al., 2008), whereas 
CYP2E1-mediated ROS production and lipid peroxidation con-
tribute to the pathogenesis of diabetes (Schafer et al., 2010) and 
nonalcoholic steatohepatitis (Abdelmegeed et al., 2012; Aubert 
et al., 2011). The increased risk of malignancy and metabolic 
diseases has been associated with elevated CYP2E1 expres-
sion and activity, which can be caused by chronic exposure to 
acetone, alcohol, isoniazid, and other compounds (Gonzalez, 
2005) or genetic polymorphisms (Catanzaro et  al., 2012; Lu 
et al., 2011; Sotsuka et al., 2011).
Determination of the role of CYP2E1 in disease would 
be greatly facilitated by real-time evaluation of CYP2E1 
expression and activity. Chlorzoxazone (CNZ), a muscle 
relaxant, has been used as a selective probe substrate for 
measuring CYP2E1 activity in vivo (Ernstgård et  al., 2007). 
CNZ assays require the intake of a pharmacologically active 
compound, multiple blood samplings, and the bioanalysis 
of CNZ and its metabolite (6-hydroxy-CNZ) (Emery et  al., 
1999; Vesell and Korsunsky, 1998), which makes it invasive 
and inconvenient. In addition, the accuracy of this method is 
affected by factors such as the dose and the involvement of 
other P450s (Ernstgård et al., 2004). A preferred solution is to 
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identify endogenous substrates that can function as noninvasive 
biomarkers of CYP2E1 activity. Cyp2e1-null mice (Lee et al., 
1996) and CYP2E1-humanized mice (Cheung et  al., 2005) 
could provide the ideal experimental platform for screening 
and characterizing endogenous biomarkers of CYP2E1 activity 
because the metabolic consequences of the loss of mouse 
CYP2E1 activity in the Cyp2e1-null mice and the introduction 
of human CYP2E1 activity in the CYP2E1-humanized mice 
can be directly examined in these models.
Metabolomics, as a high-throughput systems biology tool, 
possesses the analytical power to comprehensively examine the 
metabolism of both exogenous or endogenous substances and 
to determine the metabolizing properties of enzymes and their 
physiological functions in the biological system (Johnson et al., 
2012). In this study, a mass spectrometry–based metabolomics 
approach was applied to examine the metabolic differences 
among the wild-type (WT), Cyp2e1-null, and CYP2E1-
humanized mice. 2-Piperidone was identified and characterized 
as a potential biomarker of CYP2E1 activity.
MATErIAlS And METhOdS
Animals and chemicals. The WT, Cyp2e1-null, and CYP2E1-humanized 
mice used in this study were on the 129/Sv background. All mice were housed in 
temperature- and light-controlled rooms and were given water and pelleted chow 
ad libitum. Animal experiments were carried out in accordance with the Institute 
of Laboratory Animal Resources guidelines and approved by the National Cancer 
Institute Animal Care and Use Committee. 2-Piperidone, cadaverine, glutarim-
ide, disulfiram, acetone, and the solvents for liquid chromatography and organic 
synthesis were obtained from Sigma-Aldrich (St Louis, MO). 3-Hydroxy-2-
piperidone, 4-hydroxy-2-piperidone, and 5-hydroxy-2-piperidone were obtained 
from Ark Pharm (Libertyville, IL).
Sample collection and preparation. Pathogen-free mice (2- to 3-month-
old) were housed individually in Nalgene metabolic cages (Tecniplast, Exton, 
PA), and urine was collected for 24 h to avoid the effects of diurnal variation. 
Blood was collected by retro-orbital bleeding and processed to serum, and liver 
samples were harvested after killing. Liver microsomes were prepared by ultra-
centrifugation. All samples were stored at −80°C.
Diets and chemical treatments. NIH-31 diet was used as the maintenance 
chow for WT, Cyp2e1-null, and CYP2E1-humanized mice but was replaced 
by AIN-93G purified diet 6 days prior to chemical treatments. To determine 
the biotransformation of 2-piperidone or cadaverine in vivo, male WT mice 
were treated with 2-piperidone (ranging from 0.1 to 40 mg/kg) or cadaverine 
(20 mg/kg), respectively, by ip injection, and urine was collected for 24 h. The 
inhibition of CYP2E1 in WT mice was achieved by ip injection of disulfiram 
(20 mg/kg), whereas the induction of CYP2E1 in WT mice was achieved by ip 
injection of acetone (2 g/kg) for 3 days.
Primary hepatocyte extraction and culture. Primary hepatocytes were 
isolated from the WT and Cyp2e1-null mice using a two-step perfusion tech-
nique, which involves the sequential perfusion of the liver with a solution con-
taining EDTA and collagenase (Seglen, 1976). Cells were treated with 100µM 
of 2-piperidone or 100µM of cadaverine dissolved in DMSO. After 12- and 
24-h treatment periods at the prescribed time points, the cells were harvested 
and subjected to metabolite analysis.
Metabolomic analyses of urine and serum samples. Urine samples were 
prepared by mixing 40 µl of urine with 160 µl of 50% aqueous acetonitrile 
and centrifugation at 18,000 × g for 10 min to remove protein and particulates. 
Serum samples were denatured by the addition of 40-fold dilution of acetonitrile 
(66% vol:vol water). The supernatants were injected into the UPLC (Waters 
Corporation, Milford, MA) and metabolites separated by a gradient ranging 
from water to 95% aqueous acetonitrile containing 0.1% formic acid over a 
10-min run. An Acquity UPLC BEH C18 column (Waters) was used to sep-
arate chemical components at 35°C. The mobile phase flow rate was 0.5 ml/
min with an aqueous acetonitrile gradient containing 0.1% formic acid over a 
10-min run. The QTOF Premier mass spectrometer (Waters) was operated in 
the positive electrospray ionization mode. Capillary voltage and cone voltage 
were maintained at 3 kV and 20 V, respectively. Source temperature and des-
olvation temperature were set at 120°C and 350°C, respectively. Nitrogen was 
used as both cone gas (50 l/h) and desolvation gas (600 l/h), and argon was used 
as collision gas. For accurate mass measurement, the time-of-flight mass spec-
trometry was calibrated with sodium formate solution (ranging 100–1000 m/z) 
and monitored by the intermittent injection of the lock mass sulfadimethoxine 
([M + H]+ = 311.0814 m/z) in real time. Mass chromatograms and mass spectral 
data were acquired and processed by MassLynx software (Waters) in centroid 
format. Metabolites were quantitated via peak areas that were normalized using 
an internal standard.
Gas chromatography-mass spectrometry analysis of urine samples. 
Diluted urine samples and standard solutions containing 5µM 4-nitrobenzoic acid 
as the internal standard were applied to Waters Oasis HLB SPE columns, washed 
with water, and eluted with methanol. The eluate was dried under nitrogen, resus-
pended in acetonitrile, and derivatized with N,O-bis(trimethylsilyl)trifluoroaceta-
mide/10% trimethylchlorosilane. Samples were heated at 60°C for 30 min and then 
transferred to autoinjector vials. Gas chromatography-mass spectrometry (GC-
MS) analysis was conducted using an Agilent GC 6890N/MS 5973N system. The 
initial oven temperature of 100°C was held for 2 min, then ramped at 10°C/min, 
and held for 2 min at 220°C. The injector temperature was 200°C, and the interface 
temperature was 220°C. One microliter of sample was injected onto the column 
using helium as the carrier gas, held at a constant flow of 1 ml/min. The mass spec-
trometer was operated in scan mode (50–550 amu) with a solvent delay of 7 min.
Multivariate analysis of metabolomic data. Chromatographic and spectral 
data were deconvoluted by MarkerLynx (Waters) software. A multivariate data 
matrix containing information on sample identity, ion identity (retention time and 
m/z), and ion abundance was generated through centroiding, deisotoping, filter-
ing, peak recognition, and integration. The intensity of each ion was calculated 
by normalizing the single ion counts versus the total ion counts in the whole 
chromatogram. The data matrix was exported into SIMCA-P software (Umetrics, 
Kinnelon, NJ) and transformed by mean-centering and Pareto scaling. Principal 
components of urine were generated by principal components analysis (PCA) 
or partial least squares discriminant analysis (PLS-DA) and were depicted in a 
scores scatter plot. The ions contributing to the separation of sample groups were 
identified in the respective loadings plot (Chen et al., 2007).
Synthesis of 6-hydroxy-2-piperidone. An oven-dried 100 ml round-
bottomed flask was equipped with a stir bar and charged with glutarimide 
(0.20 g, 1.8 mmol, 1.0 eq.). The system was placed under an atmosphere of 
nitrogen, and 20 ml of dichloromethane was added. After cooling to 0°C, a 
solution of diisobutylaluminium hydride (DIBAL) in toluene (1.5M, 1.2 ml, 
1.8 mmol, 1.0 eq.) was injected over the course of 5 min. When effervescence 
had ceased, the reaction was stirred for another 10 min. Then, an additional 
portion of DIBAL (1.5M, 1.3 ml, 1.9 mmol, 1.05 eq.) was injected over the 
course of 5 min. The reaction was monitored by thin-layer chromatography and 
stirred to completion on ice.
Analysis on 2-piperidone and cadaverine in mouse chows. After dry-
ing, 100 mg of NIH-31 diet and 100 mg of AIN-93G diet were homogenized 
in acetonitrile. The supernatants were obtained through centrifuging thrice at 
10,000 × g for 10 min and diluted 10 times by acetonitrile. Five microliters of 
supernatant were injected into the liquid chromatography-mass spectrometry 
(LC-MS) or GC-MS systems. Target molecules were quantitated via peak areas 
that were normalized using an internal standard compared with standard curves 
of 2-piperidone and cadaverine.
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Statistical analysis. Experimental values are expressed as mean ± SD. 
Statistical analysis was performed using two-tailed Student’s t-test, except for 
the in vitro metabolism of 2-piperidone that was analyzed by one-way ANOVA. 
A value of p < 0.05 is considered statistically significant.
rESulTS
Urinary Metabolomics of WT and Cyp2e1-null Mice
Following LC-MS analysis of urine samples from male WT 
and Cyp2e1-null mice, a clear separation of metabolites between 
the two groups was revealed in a PLS-DA model (Fig.  1A). 
A  similar separation was observed between female WT and 
Cyp2e1-null mice (Fig. 1B). More importantly, the loading plots 
of both male and female urinary metabolomes (Figs. 1C and D) 
showed a metabolite with [M + H]+ = 100.077+ m/z as a major 
contributor to the distinctive separation of WT and Cyp2e1-null 
mice in the PLS-DA models. The elemental composition and 
chemical structure of this metabolite were proposed based on 
the accurate mass measurements and MS/MS fragmentography. 
This compound was finally determined to be 2-piperidone by a 
comparison with authentic standard (Fig. 2).
Distribution of 2-Piperidone in the Urine of WT, Cyp2e1-
null, and CYP2E1-humanized Mice
Quantitative analysis confirmed that 2-piperidone was pre-
sent at high levels in the urine of Cyp2e1-null mice but virtually 
undetectable in the WT mice (p < 0.001) (Fig. 3A). A similar 
distribution pattern of 2-piperidone was also observed in the 
urine samples of CYP2E1-humanized mice [hCYP2E1(+/+), 
mCyp2e1(−/−)], and their littermate controls [hCYP2E1(−/−), 
mCyp2e1(−/−)] (p  <  0.001) (Fig.  3B) and further confirmed 
by examining its levels in serum samples from both male and 
female WT and Cyp2e1-null mice (Fig.  3C). These results 
strongly suggested that the level of 2-piperidone in mouse bio-
fluids was highly correlated with the presence of both mouse 
and human CYP2E1.
Backcrossing of WT and Cyp2e1-null Mice to Confirm That 
2-Piperidone Is Related to CYP2E1 Expression
The correlation between 2-piperidone and Cyp2e1 genotypes 
was further examined by backcrossing of WT and Cyp2e1-
null mice. The heterozygous mCyp2e1(+/−) male and female 
mice were generated as the F1 generation. Subsequently, three 
FIg. 1. Metabolomic analysis of urine samples from the WT (● ) and Cyp2e1-null mice (○). Urine samples were analyzed in positive mode in a LC-MS 
system. Data were processed using Markerlynx and SIMCA-P+ software. (A) Scores plot of the PLS-DA model on male WT and Cyp2e1-null mice. The fitness 
(R2 value) and prediction power (Q2 value) of the model were 0.315 and 0.196, respectively. (B) Ion ([M + H]+ = 100.077+ m/z) is shown as a box which is located 
in the lower left corner of the loading plot. (C) Scores plot of the PLS-DA model on female WT and Cyp2e1-null mice. R2 value and Q2 value of the model were 
0.424 and 0.289, respectively. Loading plot of the PLS-DA model on male WT and Cyp2e1-null mice. (D) Loading plot of the PLS-DA model on female WT and 
Cyp2e1-null mice. Ion ([M + H]+ = 100.077+ m/z) is shown as a box that is located in the lower left corner of the loading plot.
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genotypes, mCyp2e1(+/+), mCyp2e1(+/−), and mCyp2e1(−/−) 
mice, were produced at the expected Mendelian ratios in the 
F2 generation after crossing the F1 mice. Similar to the par-
ent WT and mCyp2e1-null mice, the distribution of 2-piperi-
done in the urine of F2 mice was consistent with the genotypes 
in both genders, i.e., 2-piperidone was abundant in back-
crossed mCyp2e1(−/−) mice but deficient in backcrossed 
mCyp2e1(+/+) and mCyp2e1(+/−) mice (Figs. 4A and B). This 
backcrossing experiment further confirmed that 2-piperidone 
is inversely correlated to CYP2E1 expression and therefore a 
potential biomarker for CYP2E1 activity. A higher variability 
in 2-piperidone levels was noted in the females compared with 
males (Figs. 3 and 4). The mechanism of this gender variability 
is not known, although it could be due to differences in estrous 
cycle and hormones in the female mice under study.
In Vivo Metabolism of 2-Piperidone
The contrast between the high abundance of 2-piperidone in 
Cyp2e1-null mice and its low abundance in WT mice suggested 
2-piperidone as a potential CYP2E1 substrate. To investigate this 
possibility, two doses of 2-piperidone (20 and 40 mg/kg) were 
administered to WT mice. The resulting metabolomic profiles 
showed separation of 2-piperidone-treated mice from control 
mice in a dose-dependent manner (Fig. 5A). 2-Piperidone (I) and 
a metabolite with [M + H]+ = 116.0709+ m/z (II) were identified 
as the major contributors to the separation of sample groups in the 
loadings plot (Fig. 5B). Metabolite II was assumed to be a hydrox-
ylated 2-piperidone, with the possible sites of hydroxylation at 
the carbon-3, -4, -5, or -6 position of 2-piperidone. The chemical 
identity of metabolite II was finally determined to be 6-hydroxy-
2-piperidone after comparing the chromatograph and MS/MS 
fragmentography of this metabolite with a synthesized standard 
of 6-hydroxy-2-piperidone and other hydroxylated 2-piperi-
done standards (Fig.  5C; Supplementary fig.  1). The retention 
times of 3-hydroxy-2-piperidone, 4-hydroxy-2-piperidone, and 
5-hydroxy-2-piperidone were 0.48, 0.61, and 0.39 min, respec-
tively. 6-Hydroxy-2-piperidone in urine and the 6-hydroxy-2-pi-
peridone standard have a retention time of 0.53 min. The MSMS 
fragmentation of 6-hydroxy-2-piperidone in urine only matched 
the MSMS pattern of the 6-hydroxy-2-piperidone standard.
To further confirm the role of CYP2E1 in the conversion of 
2-piperidone to 6-hydroxy-2-piperidone, WT mice were treated 
FIg. 2. Identification of 2-piperidone through a comparison of MS/MS spectra. MS/MS fragmentography is shown for the fragmentograms of urinary ion 
([M + H]+ = 100.077 m/z) (top) and 2-piperidone (bottom).
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with six doses of 2-piperidone (0.1, 0.2, 1, 2, 10, and 20 mg/kg). 
In addition, disulfiram, a CYP2E1 inhibitor (Emery et  al., 
1999), was coadministered with the 20 mg/kg 2-piperidone 
dose. The level of 6-hydroxy-2-piperidone in urine increased 
dose dependently after treating 2-piperidone ranging from 
0.1 to 10 mg/kg (Fig. 6A), suggesting that 2-piperidone is the 
direct precursor of 6-hydroxy-2-piperidone. Interestingly, 
the production of 6-hydroxy-2-piperidone from the 20 mg/kg 
2-piperidone treatment was lower than that from the 10 mg/
kg 2-piperidone treatment, which could be due to substrate 
inhibition of CYP2E1 (Jones et al., 2011; Lee and Kim, 2013). 
Cotreatment of disulfiram led to the decrease of 6-hydroxy-2-
piperidone in WT mice, thus further suggesting a catalytic role for 
CYP2E1 in the biotransformation of this compound (Fig. 6A). 
Moreover, when WT mice were treated with acetone, a CYP2E1 
inducer (Bondoc et al., 1999; Sinclair et al., 2000), incubation 
of 2-piperidone with liver microsomes from control and 
acetone-treated mice showed that 2-piperidone 6-hydroxylase 
activity in mouse liver was significantly induced by acetone 
and dramatically inhibited by disulfiram (Fig. 6B). These data 
indicate that CYP2E1 is the major enzyme responsible for 
converting 2-piperidone to 6-hydroxy-2-piperidone both in vivo 
and in vitro.
Identifying Mouse Chow as a Source of 2-Piperidone 
In Vivo
In order to identify the source of 2-piderione in urine, a diet-
switching experiment was performed. The normal NIH-31 
chow, which contains both seasonal plant and animal materi-
als, was replaced with AIN-93G chow that comprised purified 
nutritional components. After feeding the AIN-93G purified 
diet, PCA analysis of urinary metabolomics did not show a clear 
separation between WT and Cyp2e1-null mice (Supplementary 
fig. 2A). 2-Piperidone was also not detected in the sera of AIN-
93G diet-fed WT and Cyp2e1-null mice (Supplementary fig. 2B). 
Therefore, the observed contrast between the feeding of NIH 
chow (Fig. 1) and the feeding of AIN-93G diet (Supplementary 
fig. 2) suggested the dietary relevance of 2-piperidone.
To determine whether the mouse chow is the only source of 
2-piperidone in vivo, a mass balance experiment was conducted 
FIg. 3. Genotype-dependent distribution of 2-piperidone. Relative abundance of 2-piperidone was expressed by the peak area normalized by internal stand-
ard. (A) Distribution of 2-piperidone in the urine of male and female WT (mCyp2e1+/+) and Cyp2e1-null (mCyp2e1−/−) mice. (B) Distribution of 2-piperidone 
in the urine of male and female CYP2E1-humanized mice (hCYP2E1+/+, mCyp2e1−/−) and their littermates (hCYP2E1−/−, mCyp2e1−/−). (C) Distribution of 
2-piperidone in the serum of male and female WT and Cyp2e1-null mice. ns, no significant difference.
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by comparing the quantity of 2-piperidone in the NIH diet 
consumed by mice with the quantity of 2-piperidone excreted 
in the urine. The amount of 2-piperidone in the NIH chow was 
determined as 87 ng/kg chow, but none was detected in the AIG-
93G purified diet. Dietary chow uptake was around 2–3 g per 
mouse per day, equivalent to 175–262 ng 2-piperidone per mouse 
per day. However, the average amount of 2-piperidone in urine 
was determined to be 507 ± 62 ng/day in a Cyp2e1-null mouse and 
6.2 ± 4.1 ng/day in a WT mouse (n = 7). The quantitative difference 
between 2-piperidone in urine and 2-piperidone in dietary intake 
suggested that in addition to its dietary source, 2-piperidone in the 
Cyp2e1-null mice might also come from endogenous metabolism.
Identification of Cadaverine as a Potential Precursor 
Metabolite of 2-Piperidone
Cadaverine is known to be metabolized to 2-piperidone 
through formation of 1-piperideine (Callery and Geelhaar, 
1984), which is subsequently metabolized to 2-piperidone via 
amine oxidase–mediated oxidation (Naila et  al., 2010). To 
examine whether cadaverine is another source of 2-piperidone 
in vivo, GC-MS analysis of urine samples was conducted. The 
result of GC-MS-based metabolomics revealed clear separation 
between WT and Cyp2e1-null mice in a PCA model (Fig. 7A). 
Among the urinary metabolites that contributed to differences 
between the two mouse lines, a higher level of 2-piperidone 
was correlated with the Cyp2e1-null mice, whereas a higher 
level of cadaverine was correlated with the WT mice (Fig. 7B).
Dietary analysis indicated that, in contrast to 2-piperidone, 
cadaverine is undetectable in either NIH chow or purified 
diet (Supplementary fig.  3). Furthermore, cadaverine was 
not detected in the urine from the mice fed purified diet but 
detected from urine of mice fed NIH diet (Supplementary 
fig. 3). To examine whether cadaverine metabolism contributes 
to the genotype-dependent distribution of 2-piperidone, 
cadaverine was administered to both WT and Cyp2e1-null 
mice fed the AIN-93G purified diet. Subsequent metabolite 
FIg. 4. The influence of backcrossing between WT and Cyp2e1-null mice on 2-piperidone distribution in urine. (A) Distribution of 2-piperidone in male 
WT, Cyp2e1-null, and F2 generation mice. The procedure of backcrossing to produce F1 and F2 generations is illustrated in the insert. The genotypes of male F2 
generation mice are shown in an inlaid image of Cyp2e1 genotyping. (B) Distribution of 2-piperidone in female WT, Cyp2e1-null, and F2 generation mice. The 
genotypes of female F2 generation mice are shown in an inlaid image of Cyp2e1 genotyping.
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analysis revealed a high abundance of 2-piperidone and a low 
abundance of cadaverine in the urine of Cyp2e1-null mice, 
while an opposite distribution pattern was found in the urine of 
WT mice, suggesting that efficient conversion of cadaverine to 
2-piperidone occurred in the Cyp2e1-null mice but not in WT 
mice (Fig. 7C). This observation on the in vivo biosynthesis of 
2-piperidone from cadaverine was further confirmed by in vitro 
incubations because primary hepatocytes from the Cyp2e1-null 
mice were far more effective than their counterparts from the 
WT mice for converting cadaverine to 2-piperidone (Fig. 7D). 
The expression of Cyp2e1 was not changed in primary 
hepatocytes of WT and Cyp2e1-null mice treated with either 
2-piperidone or cadaverine.
dISCuSSIOn
2-Piperidone, also called δ-valerolactam, is a widely used 
monomer for synthesizing polymers (nylon-5) in industry 
(Mahjoub et al., 2011). However, the appearance of 2-piperidone in 
urine and serum has not been reported previously. Metabolomic 
analysis of WT, Cyp2e1-null, and CYP2E1-humanized mice 
demonstrated that the distribution of 2-piperidone in mice 
is genotype dependent. More importantly, 2-piperidone was 
identified as a potential biomarker of CYP2E1 activity based 
on genotype-dependent distribution, backcrossing of WT and 
Cyp2e1-null mice, and in vitro assays. 2-Piperidone bears the 
structural features of typical CYP2E1 substrates, such as small 
size, ring structure, and modest hydrophilicity (Li et al., 2012). 
Indeed, the conversion of 2-piperidone to its main metabolite 
6-hydroxy-2-piperidone was inhibited by disufiram, a CYP2E1 
inhibitor, and elevated by pretreatment of mice with acetone, a 
CYP2E1 inducer. Another important observation was the dietary 
association of 2-piperidone. Two different mouse chows were 
used in this study. One is NIH-31 diet, an open-formula diet 
based on cereal and fish meal, and the other is AIN-93G diet, 
which contains refined ingredients including proteins, sugars, 
FIg. 5. Identification of 6-hydroxy-2-piperidone as a 2-piperidone metabolite. (A) Separation of control WT (□) mice from the WT mice (■) treated with 20 and 
40 mg/kg of 2-piperidone in the scores plot of a PLS-DA model on the urine metabolomes. (B) Identification of 2-piperidone (I) and 2-piperidone metabolite (II) in 
the loadings plot. (C) A comparison of MS/MS spectra of urinary 2-piperidone metabolite ([M + H]+ = 116.07 m/z) and synthesized 6-hydroxy-2-piperidone standard.
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oils, vitamins, and minerals (Reeves, 1997). 2-Piperidone was 
detected in urine from mice fed regular NIH-31 diet that con-
tains 2-piperidone but not from the mice fed AIN-93G purified 
diet that lacks 2-piperidone. Therefore, the genotype-dependent 
distribution of 2-piperidone in mouse urine can be partially 
attributed to the presence of CYP2E1-mediated metabolism of 
2-piperidone in the WT and CYP2E1-humanized mice and the 
absence of the same reaction in the Cyp2e1-null mice.
Dietary exposure of 2-piperidone could not be the sole 
source of urinary 2-piperidone in the Cyp2e1-null mice because 
quantitative analysis revealed that the daily dietary intake 
of 2-piperidone was less than the amount of 2-piperidone 
excretion in urine. Through GC-MS–based metabolomics, 
cadaverine, a common urine and semen metabolite derived 
from the decarboxylation of lysine (Bardocz, 1993; Seiler, 
2004), was defined as another potential source of 2-piperidone 
because the urinary excretion of 2-piperidone was correlated 
to the cadaverine intake in the Cyp2e1-null mice in a dose-
dependent manner. Therefore, besides its proven role in the 
catabolism of 2-piperidone, CYP2E1 can also negatively affect 
the biogenesis of 2-piperidone, in which cadaverine functions 
as a precursor of 2-piperidone. Further investigations on the 
source and metabolism of cadaverine in this study provided 
some mechanistic insights on how cadaverine can contribute to 
CYP2E1-dependent levels of 2-piperidone.
Treatment of WT and Cyp2e1-null mice with cadaverine 
resulted in more 2-piperidone in the Cyp2e1-null mice. 
In addition, a higher conversion rate from cadaverine to 
2-piperidone was observed in primary hepatocytes from 
Cyp2e1-null mice compared with hepatocytes from WT 
mice. Similar to 2-piperidone, the distribution of cadaverine 
is also diet dependent. Cadaverine was present in the urine 
from mice fed the NIH-31 diet but absent in the urine from 
the mice fed the AIN-93G diet. Because cadaverine was not 
detected in both NIH-31 and AIN-93G diets used in this 
study, the observed correlation between NIH-31 diet with 
urinary cadaverine suggest that NIH-31 diet may stimulate 
the production of cadaverine in vivo, subsequently leading to 
the increase of urinary 2-piperidone, especially in the Cyp2e1-
null mice. Thus, 2-piperidone metabolism is not only related 
to CYP2E1 and other enzymes in the WT and Cyp2e1-null 
mice but can also be altered in a diet-dependent manner. In 
fact, it was reported that consuming food rich in polyphenols, 
such as cocoa, tea, and fruit, can promote the production of 
valerolactone, an analogue of 2-piperidone in human and rat 
urine (Jurikova et al., 2011; Schantz et al., 2010; Urpi-Sarda 
et  al., 2009). Overall, the results from animal and in vitro 
incubation experiments in this study indicated that the observed 
inverse correlation between 2-piperidone and CYP2E1 can be 
attributed to the changes in the biosynthesis and degradation of 
2-piperidone. Compared with the 2-piperidone metabolism in 
the WT mice, the conversion of cadaverine to 2-piperidone was 
higher, whereas the metabolism of 2-piperidone to 6-hydroxy-
2-piperidone was lower in the Cyp2e1-null mice, leading to 
the accumulation of 2-piperidone in the urine of Cyp2e1-null 
mice. The putative metabolic events contributing to the inverse 
correlation between urinary 2-piperidone and CYP2E1 are 
outlined in Figure 8.
FIg. 6. The influence of 2-piperidone treatment and CYP2E1 activity on the production of 6-hydroxy-2-piperidone in vivo and in vitro. (A) WT mice were 
treated with 0.1, 0.2, 1, 2, 10, and 20 mg/kg of 2-piperidone by ip injection. The influence of CYP2E1 inhibitor in vivo was examined by cotreatment with 20 mg/
kg disulfiram (DSF) coadministered by ip injection with 20 mg/kg of 2-piperidone. (***p < 0.001, compared with 0.1 mg/kg of 2-piperidone treatment; ###p < 
0.001, compared with 20 mg/kg of 2-piperidone treatment). (B) 2-Piperidone ranging from 1 to 200µM was incubated with mouse liver microsomes (MLM) from 
control and acetone-treated WT mice. The influence of CYP2E1 inhibitor on microsomal incubation was examined by the cotreatment of 200µM disulfiram and 
200µM 2-piperidone (***p < 0.001, compared with the incubation using control MLM).
44 CHENG ET AL.
FIg. 7. Identification of cadaverine as a source of 2-piperidone in vivo. (A) Separation of WT (●) and Cyp2e1-null (○) mice in a PCA model on GC-MS analysis 
of urine samples. (B) Contribution of cadaverine and 2-piperidone to the separation of WT and Cyp2e1-null mice in the S-plot of urinary metabolites. (C) Levels of 
2-piperidone in the urine of WT and Cyp2e1-null mice after feeding cadaverine together with AIN-93G purified diet (***p < 0.001, compared with WT mice). (D) 
The production of 2-piperidone after incubating cadaverine with primary hepatocytes from the WT and Cyp2e1-null mice. No cadaverine was added in the control.
FIg. 8. Metabolic events contributing to the inverse correlation between urinary 2-piperidone and CYP2E1. Dietary 2-piperidone and endogenous cadaverine 
are two sources of 2-piperidone in vivo and in the urine. (A) Biogenesis and metabolic fate of 2-piperidone in the WT mice. (B) Biogenesis and metabolic fate of 
2-piperidone in the Cyp2e1-null mice.
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The applicability of 2-piperidone as a noninvasive and clini-
cal biomarker of CYP2E1 activity requires further studies to 
determine the correlation between CYP2E1 activity and the 
content of urinary 2-piperidone in humans. Data from this 
mouse-based study suggest that besides the factors that can 
affect human CYP2E1 activities, such as genetic polymor-
phism and physiological status, the influence of human diet 
on the biogenesis of 2-piperidone should also be considered. 
Proper control of these experimental factors will likely reduce 
the chance of identifying false positive or false negative cor-
relations between CYP2E1 and 2-piperidone.
In summary, this is the first study to investigate an 
endogenous biomarker of CYP2E1 expression and activity 
through metabolomics phenotyping of WT, Cyp2e1-null, and 
CYP2E1-humanized mice. The identification of a correlation 
between the levels of 2-piperidone in urine and the activity 
of CYP2E1 provides an opportunity to establish a clinically 
applicable biomarker that can be used to monitor CYP2E1 
activity through noninvasive measurements.
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